Macular Degeneration Treatment Market (By Disease Indication: Dry Age-related Macular Degeneration Treatment, Wet Age-related Macular Degeneration Treatment, Others; By Drug Class: Anti-vascular endothelial growth factor, Others; By End-user: Ambulatory Surgical Centers, Hospitals, Ophthalmic Clinics) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 160

Introduction

The global macular degeneration treatment Market is estimated to value US$ 11.4 Billion by 2026 and the market is projected to showcase 6.6% CAGR during the forecast period. The macular degeneration treatment market is driven by surge in healthcare spending and improved in healthcare infrastructure.

Market Dynamics

Rising patient population and increase inawareness about drugs for treating AMD are the major driving forces for the growth of the macular degeneration treatment market. The anti-VEGF therapies segment is expected to hold largest share and is likely to drive the global market. The key manufacturers are tapping opportunities to launch therapies for geographic atrophy that directly have a positive impact on the growth of the macular degeneration treatment market. Therefore, enrolment in clinical trials is expected to rise in the upcoming years.

Market Insights

Growing prevalence of AMD is expected to boost the global market, while this could be an obvious growth factor of the market, there are other factors that are expected to propel the market in the near future. For instance, increase in healthcare spending and health awareness among patients are estimated to boost the market growth. Also, the launch of advanced medicines in age-related macular degeneration treatment is also projected to drive the global macular degeneration treatment market.

Continuous introduction of innovative products that is used for treatment of atrophy, dry age-related macular degeneration treatment, and wet age-related macular degeneration treatment arethe growth enablers of macular degeneration market. Various drugs are introduced in market such as anti-VEGF and others which is projected to boost the demand for macular degeneration treatment globally. Mainly, there is continuous innovation to manufacture various types of drugs to treat dry age-related macular degeneration treatment which can beone of the major factor that is driving the growth of macular degeneration treatment market.

Market Classification

The global macular degeneration treatment market is segmented into disease indication, drug class, end-user, and region. On the basis of disease indication, the global macular degeneration treatment market is segmented into dry age-related macular degeneration treatment, wet age-related macular degeneration treatment, and others. On the basis of drug class, the global macular degeneration treatment market is segmented into anti-vascular endothelial growth factor (anti-VEGF) and others. On the basis of end-user, the global macular degeneration treatment market is segmented into ambulatory surgical centers, ophthalmic clinics, and hospitals. On the basis of region the global macular degeneration treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Based on the drug class, the global macular degeneration treatment market can bemajorly segmented into twosub-segment, which areanti-vascular endothelial growth factor (anti-VEGF) and others. The anti-VEGF segment is expected to hold major share of the global macular degeneration treatment market due to the extensive utilization as it is more reliable and effective drug compared to others.

Regional Insights

North America region is expected to dominate the global macular degeneration treatment by holding major share. The dominance in this region is due to the increasing number of FDA approved drugs as well as increased adoption of age-related macular degeneration diseases. This will have a positive impact on the growth of the macular degeneration treatment market.Asia Pacific is expected to grow at a significant rate due to the rise number of patient population and increase in healthcare expenditure in this region.

Market Participants

The prominent players operating in the macular degeneration treatment market are GlaxoSmithKline plc, Novartis AG, Bayer AG, Neurotech Pharmaceuticals, Inc., Ophthotech Corporation, F. Hoffmann-La Roche Ltd., StemCells Inc., Pfizer, Inc., Sanofi, Santen Pharmaceuticals, Allergan, Inc., and Valeant Pharmaceuticals etc.

Key manufacturers in the global market are focused on continuous innovation of drugs and expand their product portfolio to offer effective and high quality drugs used to treat AMD.Moreover, the players associated with the global macular degeneration treatment market are focusing mainly on product innovation, strategic agreements, and developing partnerships with other players in the healthcare industry in order to gain major share of the macular degeneration treatment market.

Market Segmentation

Market By Disease Indication

  • Dry Age-related Macular Degeneration Treatment
  • Wet Age-related Macular Degeneration Treatment
  • Others

Market By Drug Class

  • Anti-vascular endothelial growth factor
  • Others

Market By End-user

  • Ambulatory Surgical Centers
  • Hospitals
  • Ophthalmic Clinics

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA


Cart Summary


1